Skip to Content

Posts tagged with "Drug Industry History"

  • Business and Markets

    Drug Industry Consolidation Refuses To Arrive So Quickly

    Anyone who’s watched the biopharmaceutical landscape over the years is familiar with two large forces that reshape the list of companies in the area: on one end, you have mergers and acquisitions that decrease the number of firms, and on the other you have startups that increase it. How have these two been balancing out?… Read More
  • Drug Assays

    Experiences With Phenotypic Screening?

    Very little blogging time today, but I wanted to throw a question out to the readership instead. I’m at the Keystone conference on Phenotypic Drug Discovery, so here’s a relevant topic: what are your own experiences with phenotypic screening? Background for those outside the field: broadly speaking, you can sneak up on a drug by… Read More
  • Business and Markets

    Institutional Memory

    This is a topic that came up in the comments section of a post last week, but it’s important enough that I wanted to give it some exposure here on the front page. It was a question from someone outside the industry, who asked about how companies can retain “institutional memory”, what with all the… Read More
  • Academia (vs. Industry)

    Targets Versus Drugs

    There was a comment on the blog the other day about how there are people in academia who feel that the discovery of a new target or pathway is basically finding a new drug, and that the rest is “technicalities”. I’ve encountered that view of the world before (Donald Light/Rebecca Warburton, Marcia Angell, and similarly Arnold… Read More
  • Drug Development

    2018 Drug Approvals: A Closer Look

    Let’s have a look at the recent new drug approvals. 2018 was quite a year, by the numbers. C&E News has a comprehensive roundup: 59 approvals (versus 46 in 2017, which was already a record by itself), and about two-thirds of those small molecules. There are some very interesting molecules in the list, and I… Read More
  • Biological News

    Precision Medicine Real Soon Now

    Here’s a strongly opinionated look at where the “precision medicine” field is these days, and I think that this is just the sort of article that the field (and the journalists covering it) need to see, whether you agree with it or not: In 1999 Francis Collins published a foundational document of precision medicine entitled… Read More
  • Chemical News

    Defending Drug Synthesis

    This article from Science is a good look at the scientific state of organic synthesis in the pharmaceutical industry. It covers a range of topics which will be familiar to regular readers of this blog as well: synthetic advances such as late-stage functionalization, new bond-forming techniques (photoredox chemistry in particular), the intersection… Read More
  • Cancer

    PI3K Inhibitors: You’re Doing It Wrong

    Now here’s an interesting connection between cancer and metabolism, with what look to be direct implications for therapy. A large research team (mostly working out of Weill Cornell) reports some new and important details about PI3K inhibitors, a class of kinase inhibitors that has seen a very large amount of development work indeed. I’v… Read More
  • Alzheimer's Disease

    Failure Shouldn’t Be Such an Orphan

    The drug industry has  a huge stockpile of results on projects that have not worked. That much is clear – clinical success rates continue at about 10%, on average, so we have a steady stream failures of all kinds, for all reasons. It would be foolish not to learn as much as we could from… Read More
  • Biological News

    Engineering Biology, For Real?

    Any article titled “How to Engineer Biology” is going to get a look from me – and when I’m referenced in the opening paragraphs, especially so. This is a piece by Vijay Pande in Scientific American, and I get called out for my naming of the “Andy Grove Fallacy” (found in this post and the… Read More
123...